News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Positive data from an additional 5 patients in the first part of the PLIANT study

August 26, 2014

PledPharma AB
Company Announcement

Positive data from an additional 5 patients in the first part of the PLIANT

Stockholm, 2014-08-26 13:00 CEST (GLOBE NEWSWIRE) -- 
In total 11 patients have been treated in the open part of the study and
preliminary analysis of the raw data indicated that PledOx® reduced the severe
chemotherapy-induced side effects. 

The new data showed that PledOx was well tolerated by the additional 5 patients
treated with the antibody Avastin (bevacizumab) in combination with FOLFOX

With this, the open part of the study with a total of 11 patients is reported.
The open part of the study was performed in order to determine tolerability and
the correct dose level. 

Nine of these 11 patients underwent at least 6 cycles of FOLFOX and none of
these patients showed a grade 2 or worse neuropathy against an expected outcome
of at least two patients. 

These data also indicated a reduction of serious blood-related side effects
with the 
 5 μmol/kg dose of PledOx.

The combination with the antibody bevacizumab as adjunctive therapy to
chemotherapy is common especially in the United States, but occurs in all
countries participating in the study. 

About PledOx®
PledOx (calmangafodipir) is a compound that among other properties prevents
severe side-effects of chemotherapy in cancer treatment. PledOx has been shown
to protect against "oxidative stress" - a condition in which the cell's most
important protection is not sufficient against the levels of reactive
oxygen/nitrogen species generated as a result of the chemotherapy treatment. By
mimicking the enzyme manganese superoxide dismutase (MnSOD), PledOx boosts the
cells endogenous protection and thereby prevents side-effects that otherwise
would arise as a result of the "oxidative stress". 

About Bevacizumab
Brand name Avastin®, (Genentech / Roche) is an angiogenesis inhibitor that
slows the growth of new blood vessels. Bevacizumab specifically blocks a growth
factor in blood vessels. This reduces the growth of blood vessels in the tumor,
which shuts off the supply of blood to the tumor. Bevacizumab is used in the
treatment of metastatic cancer of various origin including colorectal, mammary,
kidney, and lung cancer. 

About colorectal cancer
Colorectal cancer is the third most common cancer related cause of death in the
western world. Annually 450,000 people become ill in colorectal cancer on the
seven largest markets in the Western world. First line treatment in colorectal
cancer is a combination treatment called FOLFOX (FOLinate, 5-Fluorouracil
(5-FU), and OXaliplatin). FOLFOX gives rise to a better outcome than previous
treatments, but severe side-effects constitute a significant problem. The
side-effects result in that the planned chemotherapy dose cannot be
administered. Less than half of the patients do not receive the prescribed
dose. Thus, there is a huge medical need to reduce the side-effects of FOLFOX. 

For further information, please contact:

Jacques Näsström, CEO

+46 737 13 09 79

About PledPharma

PledPharma is a Swedish pharmaceutical company that develops new therapies for
the treatment of life threatening diseases. The initial objective is to develop
a drug, PledOx®, which reduces severe side-effects associated with
chemotherapy. The current market for supportive cancer care is some USD 10
billion. PledPharma also evaluates an existing medicines possibility to reduce
the damage that occurs on the heart muscle when patients suffer from acute
myocardial infarction. In addition to these projects, the company is also
evaluating opportunities of using our technology platform in additional areas
where there is a significant unmet medical need. PledPharma has the potential
to offer patients valuable and unique treatments for serious life-threatening
diseases where there is an opportunity fast registration in the US through
"breakthrough therapy" designation. This means that the company has the
potential to offer shareholders a good return on their investment. PledPharma
(STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is
the Certified Adviser. For further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10